Opportunities and Possibilities: Cancer Immunotherapy in the Management of GI Cancers
The latest advances in immunotherapy for CRC, HCC, and gastroesophageal cancers are explored in these 3 columns.
This activity is intended for oncologists, gastroenterologists, and other healthcare professionals who treat patients with gastrointestinal (GI) cancers.
The goal of this activity is to increase understanding of the advances and challenges of using checkpoint inhibitors in the treatment of patients with GI cancers.
Learning Objectives:
- Have increased knowledge regarding the clinical trial data on the use of immune checkpoint inhibitors (ICIs) alone or in combination in patients with advanced or metastatic GI cancers
- ICI treatment strategies for patients with GI cancers in the community oncology setting
Approximate Time to Complete: 1 hour
Credit Available: November 27, 2019 - November 27, 2020
Developed through a partnership between SITC and Medscape.
Additional Resources for Clinicans from SITC:
AMA PRA Category 1 Credit(s)™: 1.00
ABIM MOC Part 2 Credits: 1.00